News | October 25, 2021
Biocon Q2FY22 in line with estimates, better margins: ICICI Direct
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
Early-stage research suggests the potential to prevent and treat all dengue serotypes and builds on Johnson & Johnson's work to advance science against emerging and entrenched global public health threats
The company plans to submit the IND application by the end of 2021
Subscribe To Our Newsletter & Stay Updated
